Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Operating Expenses (2016 - 2025)

vTv Therapeutics' Operating Expenses history spans 12 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 60.62% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $32.8 million, up 30.21%, while the annual FY2025 figure was $32.8 million, 30.21% up from the prior year.
  • Operating Expenses for Q4 2025 was $7.9 million at vTv Therapeutics, down from $10.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $11.1 million in Q4 2021 and bottomed at $4.0 million in Q2 2022.
  • The 5-year median for Operating Expenses is $6.5 million (2024), against an average of $6.7 million.
  • The largest annual shift saw Operating Expenses surged 143.34% in 2021 before it plummeted 42.87% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $11.1 million in 2021, then tumbled by 42.87% to $6.4 million in 2022, then decreased by 25.9% to $4.7 million in 2023, then rose by 4.29% to $4.9 million in 2024, then surged by 60.62% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Operating Expenses are $7.9 million (Q4 2025), $10.7 million (Q3 2025), and $7.7 million (Q2 2025).